Zylö and Ferndale Enter into Exclusive Development and Supply Agreement

News provided by

Feb 12, 2019, 09:06 ET

GREENVILLE, S.C., Feb. 12, 2019 /PRNewswire/ -- Zylö Therapeutics, a life science innovator, announced that it entered into an exclusive development and supply agreement with Ferndale Pharma Group to supply Z-pods™ with the aim of incorporating these into a selected product. The parties will also investigate the potential for incorporating Z-pods™ into other products. Zylö has granted exclusivity to Ferndale for certain market categories in the U.S. and Canada. Other terms were not disclosed.

Z-pods™ are highly engineered microscopic particles that can topically deliver a therapeutic payload over an extended 12-48 hour period. The technology was developed to harness the therapeutic power of nitric oxide, perhaps the most versatile molecule within the human body. Other payloads include lidocaine, benzocaine, curcumin, resveratrol, vitamin E, and cannabidiol.

Michael Burns Ph.D., president of Ferndale Pharma Group, commented, "We are impressed with Zylö's proprietary Z-pods™ delivery system and are confident this patented technology can enhance product performance."

Added Scott Pancoast, chief executive officer of Zylö, "We look forward to partnering with Ferndale, a company that is at the forefront of consumer-health innovation."

About Ferndale Pharma Group Inc.: Ferndale is a fully integrated holding company, whose Ferndale Healthcare® subsidiary serves several key specialty markets that target disease states ranging from benign anorectal disorders to various skin conditions. The company's mission is to provide high-quality, value-added products that help patients get back to what matters most in their lives—living well. Many of Ferndale's products are leaders in their respective categories. Ferndale Pharma Group is committed to ensuring that the best interests and needs of those who use their products receive the utmost consideration and to providing healthcare professionals, patients, business partners, and associates with trusted service and valued expertise.

About Zylö Therapeutics: Zylö has developed an innovative topical delivery system that solves the short duration-of-effect problem that plagues many therapeutic agents. The system uses xerogel-derived particles, called Z-pods™, to extend duration of effect and to enhance product performance. The Z-pods™ serve as a virtual dermal patch, but without the hassle, the cost, and the disposal burden of a patch. Notably, the Z-pod™ technology platform has successfully harnessed the therapeutic potential of nitric oxide (NO), one of the most powerful—and short-lived— biomolecules produced by our bodies, but produced at declining rates as we age, contributing to a myriad of issues.

Scott R. Pancoast, CEO

(858) 775-6710

[email protected]

www.zylotherapeutics.com

SOURCE Zylo Therapeutics Inc.